What is Radformation?
Radformation operates at the intersection of oncology and software engineering, focusing on the development of intelligent tools that automate radiation treatment planning. By standardizing these intricate processes, the company aims to mitigate the variability in care delivery, ensuring that patients receive consistent, high-quality treatment regardless of their geographic location. Their platform empowers clinicians to reduce the time required for planning while simultaneously enhancing safety protocols, effectively addressing the operational bottlenecks that often hinder efficient cancer treatment delivery.
In an industry where precision is paramount, Radformation's commitment to automation serves as a vital catalyst for clinical productivity. By streamlining the workflow, the company not only supports healthcare providers in managing increasing patient volumes but also contributes to the broader goal of reducing the global impact of cancer through technological innovation.
How much funding has Radformation raised?
Radformation has raised a total of $2.6M across 3 funding rounds:
Private Equity
$663K
Angel/Seed
$1.6M
Debt
$350K
Private Equity (2017): $663K, investors not publicly disclosed
Angel/Seed (2018): $1.6M led by Brooklyn Bridge Ventures
Debt (2020): $350K supported by PPP
Key Investors in Radformation
Brooklyn Bridge Ventures
Brooklyn Bridge Ventures is a venture capital firm specializing in early-stage investments, providing critical support to startups as they navigate the initial phases of market entry and product development.
PPP
Public-Private Partnership
Undisclosed Investors
What's next for Radformation?
With the recent influx of capital, Radformation is poised to accelerate its product development roadmap and expand its footprint within the global healthcare market. The strategic focus will likely center on deepening the integration of its software within existing hospital information systems and enhancing the diagnostic capabilities of its automated planning tools. As the company scales, it will continue to prioritize the standardization of care, aiming to bridge the gap in oncology services for underserved populations.
Looking ahead, the firm is expected to leverage its enterprise-level funding to forge new clinical partnerships and invest in research that further validates the efficacy of its automated solutions. By maintaining its focus on clinical excellence and operational efficiency, Radformation is set to remain a pivotal force in the evolution of modern radiotherapy.
